

# FluCov Influenza Activity Report #19

2 April 2024


## Take home: elevated but decreasing influenza activity in the Northern Hemisphere

- North America and Europe:** In the United States, influenza activity remains elevated nationally, but decreased with moderate to high activity in only a few states and minimal to low activity in most. In Europe, influenza activity also remains elevated with a decreasing trend. In week 11/2024, Denmark, Italy, Spain and the UK report <10% positivity, France and Germany reported 10-20% positivity.
- Asia:** Influenza detections decreased in China. Overall positivity rate also decreased in week 12/2024, compared to week 11, with very low activity (<10% positivity) in Northern China and low activity (10-20% positivity) in Southern China.
- Circulating virus:** Globally, all seasonal influenza viruses except B/Yamagata are circulating. While B/Victoria predominated in China, the US and Canada, A(H1N1)pdm09 dominated circulation in Europe.
- Vaccine match:** US (CDC) reports that vaccine components are well-matched to circulating A(H1N1)pdm09, B/Victoria and A(H3) clades. The same is true for Europe (ECDC) with the exception that some A(H3) viruses (2a.3a.1 clade) are less well-matched (ERVISS).
- Influenza Viruses of Pandemic Potential:** A case of influenza A(H1N2)v was reported by the US on 29 March, the infected child had by then recovered (promed). A human case of avian influenza A(H5N1) was reported by the US on 1 April, the patient had been exposed to infected cows (promed).
- COVID hospitalizations:** Continued to decrease in England, the EU, and the US, after a peak around the end of 2023.

## Positive Influenza tests (%)


**Note:** the positivity rate graphs for France, Germany, Italy, and the United Kingdom were last updated week 11/2024

— Season 2023/2024   
 — Season 2022/2023   
 — Season 2021/2022   
 — Average of pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]



## Weekly COVID-19 hospital admissions

(England, EU/EEA, US – admissions/100,000)



Displayed data is the most recent reported; it is possible that there may be a delay in reporting. Countries & inclusion dates for EU/EEA data vary markedly each week.

### Data sources & details

China:	China CDC
US:	FluView (Clinical Laboratories)
Spain:	ERVISS
DK:	WHO FluNET (non-sentinel)
All others:	WHO FluNet (sentinel)
COVID:	US (Department of Health and Human Services) EU (ERVISS), England (UKHSA)
Vaccine match:	US (CDC), EU (ERVISS)

### A Nivel publication

FluCov team: Bronke Boudewijns, Susanne Heemskerck, Marco Del Riccio, Daan van Kooten, Saverio Caini, Caroline Schneeberger.

[FluCov Influenza Activity Report #19: 2 April 2024](#). Netherlands, Utrecht: Nivel, 2024

### Websites for more information

Project Website: <https://www.nivel.nl/en/flucoV>

FluCoV Dashboard: <https://www.nivel.nl/en/flucoV-dashboard>

### Funding

The Nivel FluCov project is funded by Sanofi